Clinical efficacy of nitric oxide nasal spray (NONS) for the treatment of mild COVID-19 infection
- Resource Type
- Authors
- Stephen Winchester; Sarah John; Isaac John; Kashif Jabbar
- Source
- The Journal of Infection
- Subject
- 0301 basic medicine
Microbiology (medical)
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19)
medicine.medical_treatment
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
030106 microbiology
Nitric Oxide
Placebo
Gastroenterology
Virus
Nitric oxide
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Internal medicine
medicine
Humans
030212 general & internal medicine
Antiviral
Viral shedding
Letter to the Editor
Saline
SARS-CoV-2
business.industry
Prevention
Nasal Spray
COVID-19
Nasal Sprays
Coronavirus
Treatment
Treatment Outcome
Infectious Diseases
chemistry
Nasal spray
RNA, Viral
Antimicrobial
business
- Language
- ISSN
- 0163-4453
Baek et al.1 investigated the duration of COVID-19 virus shedding in infected patients and demonstrated that even in patients demonstrating prolonged viral clearance, the virus was no longer viable after 15 days post onset of symptoms. Our study aimed to measure whether nitric oxide nasal spray (NONS) further accelerates this reduction in SARS-CoV-2 RNA load versus a control arm with saline spray. Our study recruited 80 participants who were divided into a NONS treatment arm or a placebo arm to test the efficacy of NONS as a treatment for mild COVID-19 infection.